logo
Share SHARE
FONT-SIZE Plus   Neg

AstraZeneca Advances MedImmune's Benralizumab To Phase III In Severe Asthma

AstraZeneca (AZN.L,AZN) said it has begun the Phase III Windward programme for benralizumab, a potential treatment for severe uncontrolled asthma developed by MedImmune, the company's global biologics research and development arm. The aim of CALIMA, the first trial in the Windward programme, is to determine whether benralizumab reduces the number of exacerbations in patients with severe asthma that remains uncontrolled, despite receiving high doses of inhaled corticosteroids combined with a second controller like long-acting beta agonist.

Benralizumab is a monoclonal antibody binding to the interleukin-5 receptor, that depletes eosinophils, a type of white blood cell, which play a critical role in the cause and severity of asthma and asthma exacerbations. Emerging evidence demonstrates that for patients with elevated eosinophil counts, treatment with an IL-5 inhibitor in addition to guideline-based strategies may increase their asthma control and decrease the frequency of asthma attacks.

The CALIMA trial would evaluate the safety and effectiveness of benralizumab in actively reducing exacerbations in patients with uncontrolled asthma, and assess the benralizumab effect on lung function, asthma symptoms and other asthma control measures, as well as emergency room and hospitalisation rates due to asthma.

The efficacy and safety data from this trial supported the progression of benralizumab into our Phase III programme. These results are likely to be shared at a scientific conference in the first half of 2014. Benralizumab is in-licensed from BioWa, Inc., a subsidiary of Kyowa Hakko Kirin Co., Ltd.

by RTT Staff Writer

For comments and feedback: editorial@rttnews.com

Business News

Quick Facts

Editors Pick
Consumers in Nigeria are calling for a boycott of Coca-Cola products sold in the African nation after a high court judge ruled that the products could be "poisonous". Justice Adedayo Oyebanji of the Lagos High Court ruled that high levels of benzoic acid and sunset additives in Coca-Cola's soft drinks could pose a health risk to consumers when mixed with ascorbic acid, commonly known as Vitamin C. Charles Murphy, a partner at New York hedge fund Paulson & Co., fell to his death after jumping out of a hotel window in Manhattan on Monday. Murphy was found dead on the fourth-floor terrace of the Sofitel New York Hotel after he jumped from a window on the 24th floor. Internet media company BuzzFeed is preparing to go public in 2018, media site Axios reported Wednesday, citing industry sources. New York-based BuzzFeed was founded in 2006 by Jonah Peretti and John Johnson III as a viral lab, focusing exclusively on tracking viral content.
comments powered by Disqus
Follow RTT